GE HealthCare (Nasdaq: GEHC) Launches AI-Powered Prostate Volume Assist (PVA) Software Feature for Urology GE HealthCare, a global leader in ultrasound-guided solutions in urology, has introduced the Prostate Volume Assist (PVA), an artificial intelligence (AI) software feature tailored for urological applications. This innovative tool aims to aid clinicians in prostate imaging, biopsies, and treatment guidance, enhancing workflow efficiency and facilitating rapid capture of prostate volume. With PVA, urologists benefit from automated calculations and measurements of the prostate with a simple one-click process.
Accurate assessment of prostate volume is crucial in diagnosing and treating various prostate conditions, including prostate cancer, where precise calculations play a vital role in determining prostate-specific antigen density (PSAD), an essential metric for disease detection and management. Prostate cancer remains a significant health concern globally, contributing to a considerable portion of cancer cases and related fatalities among men.
Fredrik Gran, Head of Innovation, Surgical Visualization and Guidance, Ultrasound at GE HealthCare, emphasized the transformative potential of Prostate Volume Assist, which streamlines the traditionally manual and labor-intensive process of determining prostate volume. By leveraging artificial intelligence, PVA delivers results within seconds, offering urologists invaluable support in optimizing workflow efficiency and delivering precision care.
The PVA feature will be integrated into GE HealthCare’s existing ultrasound platforms, including bkActiv, bk3000/5000, and bkSpecto, enhancing the versatility of these systems in assisting clinicians with treatment planning and execution. These platforms boast advanced features such as automatic image optimization and high-quality ultrasound guidance, further empowering urologists in their clinical practice.
Urvi Vyas, General Manager, Surgical Visualization and Guidance, Ultrasound at GE HealthCare, underscored the company’s commitment to advancing urological care through innovative technologies like Prostate Volume Assist. This cutting-edge solution promises to optimize workflows, facilitate surgical procedures, and furnish urologists with critical information necessary for informed treatment decisions.
PVA, available on the bkActiv, bk3000/5000, and bkSpecto platforms, will be accessible in key markets worldwide. GE HealthCare will showcase this groundbreaking AI technology at prominent urology conferences, including the European Association of Urology Congress in Paris and the American Urological Association Annual Meeting in San Antonio.
For additional details on Prostate Volume Assist (PVA), please visit: [link].
